Ascletis Pharma has received US FDA Investigational New Drug (IND) clearance to advance ASC30, its oral small-molecule GLP-1 receptor agonist, into a Phase II diabetes study.
This marks ASC30’s formal entry into the type 2 diabetes (T2D) clinical pathway.
Phase II Study: What to Know
The upcoming Phase II trial is designed to test ASC30 in adults with T2D.
Study design
- 13-week, randomized, double-blind, placebo-controlled
- Multi-centre trial across the United States
- ~100 participants with type 2 diabetes
Dose arms
- ASC30 tablets: 40 mg, 60 mg, 80 mg
- Matching placebo
- Randomization ratio: 2:3:3:2
- Weekly titration from 1 mg to target dose
Timeline
- Enrollment expected to begin Q1 2026
Primary and Secondary Endpoints
Primary endpoint
- Mean change from baseline in HbA1c at 13 weeks
Key secondary endpoints
- Fasting blood glucose reduction
- Change in body weight
- Safety and tolerability
Why This Matters: Strong Obesity Phase II Data?
The diabetes study builds on recently completed 13-week Phase II obesity data for ASC30.
Key obesity trial results
- 125 participants with obesity or overweight
- Once-daily oral dosing
- Statistically significant, dose-dependent weight loss
Placebo-adjusted mean weight loss
- 20 mg: 5.4%
- 40 mg: 7.0%
- 60 mg: 7.7%
- No weight-loss plateau observed
Tolerability highlights
- Vomiting rate ~50% lower than published orforglipron data
- GI tolerability comparable to orforglipron Phase III ATTAIN-1
- Treatment discontinuation due to AEs: 4.8%
What Makes ASC30 Different?
ASC30 is not another injectable GLP-1. It is:
- A small-molecule GLP-1R agonist
- Fully biased agonist
- Designed for once-daily oral dosing
- Also suitable for monthly to quarterly subcutaneous dosing
This flexibility positions ASC30 for both treatment and maintenance therapy.
Leadership Perspective
“IND clearance for this Phase II diabetes study is a significant milestone,” said Dr. Jinzi Jason Wu, Founder and CEO of Ascletis.
The FDA clearance expands ASC30 into the large and competitive diabetes market, strengthening its commercial potential.
Ascletis’ Broader Metabolic Pipeline
Ascletis is building a diversified metabolic portfolio using in-house platforms. Key assets include:
- ASC30: Oral GLP-1R agonist
- ASC36: Once-monthly amylin receptor peptide agonist
- ASC35: Monthly GLP-1R/GIPR dual agonist
- ASC37: Oral GLP-1R/GIPR/GCGR triple agonist
All programs are developed using proprietary AI-driven drug discovery and long-acting delivery technologies.
Bottom Line
ASC30 now sits at the intersection of:
- Oral GLP-1 convenience
- Strong early efficacy
- Competitive GI tolerability
- Expansion into diabetes after obesity success
If Phase II diabetes data mirrors obesity results, ASC30 could become a serious oral GLP-1 contender.
